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Purine nucleoside phosphorylase (PNP) is a target
for leukemia, gout, and autoimmune disorders.
Dynamic motion of catalytic site loops has been
implicated in catalysis, but experimental evidence
was lacking. We replaced catalytic site groups
His257 or His64 with 6-fluoro-tryptophan (6FW) as
site-specific NMR probes. Conformational adjust-
ments in the 6FW-His257-helical and His64-6FW-
loop regions were characterized in PNP phosphate-
bound enzyme and in complexes with catalytic site
ligands, including transition state analogs. Chemical
shift and line-shape changes associated with these
complexes revealed dynamic coexistence of several
conformational states in these regions in phosphate-
bound enzyme and altered or single conformations
in other complexes. These conformations were also
characterized by X-ray crystallography. Specific
19F-Trp labels and X-ray crystallography provide
multidimensional characterization of conformational
states for free, catalytic, and inhibited complexes of
human PNP.
INTRODUCTION
Human purine nucleoside phosphorylase (PNP) is essential
for the purine recycling pathway involving the degradation
and synthesis of DNA and RNA. It catalyzes the reversible
phosphorolysis of purine (deoxy)-ribonucleosides to the corre-
sponding purine base and (20-deoxy) ribose 1-phosphate (Fig-
ure 1A) (Schramm, 2005; Stoeckler et al., 1978, 1980). The
genetic deficiency of human PNP activity induces apoptosis
in activated T cells, whereas other cells and tissues remain
unaffected (Giblett et al., 1975). The transition-state structures
of bovine and human PNPs have been solved by a combination
of experimentally determined kinetic isotope effects coupled
with theoretical calculations (Kline and Schramm, 1993; Lew-
andowicz and Schramm, 2004). Stable chemical mimics of
these transition states have produced four generations of pico-
molar transition state analog inhibitors (Ho et al., 2010) (Fig-
ure 1B). Two PNP inhibitors are in clinical trials for leukemia
and gout, and a third shows antimalarial effects in Aotus212 Chemistry & Biology 20, 212–222, February 21, 2013 ª2013 Elseprimates (Balakrishnan et al., 2010; Hollister et al., 2011; Cas-
sera et al., 2011).
Human PNP is a homotrimer (32 kDa per monomer) with
catalytic sites located near intersubunit interfaces (Figure 2A).
Crystal structures of human PNP in complex with substrates
and transition-state (TS) analogs (Figure 1B) have defined the
active-site residues in contact with the purine nucleoside and
the phosphate nucleophile, confirming that the reaction occurs
in a three-centered mechanism (purine-ribocation-phosphate)
(de Azevedo et al., 2003; Koellner et al., 1997; Rinaldo-Matthis
et al., 2008; Shi et al., 2004). The PNP active-site residues inter-
acting closely with substrate (inosine) or transition-state analog
(DADMeImmG) are Asn243, Glu201, His257, Phe200, Tyr88,
Met219, and Phe159 (from the adjacent subunit). Residues
Ser33, His 64, Arg84, His86, Ala116, Tyr192, and Ser220
interact with the phosphate nucleophile (Figure 2B shows
only residues Asn243, His257, Ser33, His64, and His86 for
clarity).
A comparison of the sulfate-bound hPNP (Protein Data Bank
[PDB] ID code 1M73) and the phosphate + DADMeImmG-bound
hPNP (PDB code 3PHB) crystal structures reveal two major
conformational alterations upon binding of substrates or transi-
tion-state analogs (Figure 2B). The His257-helix and His64-
loop adopt an open conformation and are directed away from
the active site in the sulfate-bound structure, whereas the
inhibitor + phosphate tertiary complex shows a closed confor-
mation, with these residues closer to the active site and within
H-bonding distance of ligands (Figure 2B). His257 of PNP is in
hydrogen bond distance of the 50-OH of the ribosyl group and
is a key residue in positioning the ‘‘oxygen stack’’ (O50-O40-Op)
that contributes to catalysis through a vibrational promoting
mode of the three oxygen atoms. This ‘‘oxygen stack’’ has
been proposed to provide electron density changes to destabi-
lize the ribosyl group to form the carbocation transition state
(TS) and thereby enhance departure of the purine-based leaving
group (Figures 1A and 2B) (Murkin et al., 2007; Saen-Oon et al.,
2008a). His64 is located in an unstructured and flexible loop
region that changes between open, intermediate, and closed
conformations depending on the ligand bound to the active
site. The range of motion of this loop is from 17A˚ away from
the active site in guanine-bound PNP (open loop conformation),
to 12.5A˚ away from the active site in a phosphate-bound form
(intermediate loop conformation), and finally to a phosphate +
inhibitor-bound form, where His64 is in hydrogen bond dis-
tance of the phosphate nucleophile (closed-loop conformation)
(Figures 2B, 3C, and 3D). These differences observed in thevier Ltd All rights reserved
Figure 1. Phosphorolysis Reaction Cata-
lyzed by Human PNP and Chemical Struc-
ture of Four Generations of PNP Inhibitors
(A) The reaction occurs via ribosyl C1-migration
from base to phosphate nucleophile to effect
nucleophilic displacement by electrophile migra-
tion. The mechanism is SN1-like through a fully
formed ribocation transition state. Ribose
1-phosphate and the purine base are products.
(B) Four generations of transition state analog
inhibitors, ImmH, DADMeImmG, DATMeImmH,
and SerMeImmH.
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catalytic cycle (Murkin et al., 2007, 2008). Molecular dynamic
calculations of human PNP also predict these regions to be flex-
ible (Hirschi et al., 2010).
Laser-induced temperature-jump spectroscopy previously
characterized the conformational dynamics of the catalytic
site Phe159 loop located near the ribosyl region of bound reac-
tants (Ghanem et al., 2009b). A Phe159Trp mutation in Leuko-
PNP (Trp-free PNP, where the three native tryptophan residues
were replaced by tyrosines; Ghanem et al., 2008) was used as
a reporter group to probe the motions of the catalytic site
loop. Here, we introduce a single 6-fluoro-tryptophan (6FW)
into the H257W-Leuko-PNP and H64W-Leuko-PNP mutants
at the His257 and His64 positions, respectively. These fluori-
nated PNP mutants (H257-6FW-Leuko-PNP and H64-6FW-
Leuko-PNP) were employed as active-site reporters for 19F
nuclear magnetic resonance (NMR). A powerful application of
19F-NMR is to probe proteins of known structure in solution,
where the sensitivity of the 19F resonance to its molecular envi-
ronment can reveal structural and kinetic features of protein
conformation and dynamics (Kitevski-LeBlanc and Prosser,
2012). NMR spectral changes in ligand-bound PNP complexes
revealed the coexistence of distinct conformational states for
both regions (His257-helix and His64-loop). X-ray crystal struc-
tures of the same ligand-bound protein complexes provide
structural benchmarks to complement the 19F-NMR dynamic
observations.Chemistry & Biology 20, 212–222, February 21, 2013RESULTS
Steady-State Kinetics and
Transition State Analog Inhibition
The effects of mutations and incor-
poration of 6FW on the steady-state
kinetics of inosine phosphorolysis and
DADMeImmG inhibition were compared
to native and Leuko PNP (Table 1). The
H257W-Leuko-PNP mutant has a kcat
reduced by 16-fold and a Km increased
by 2 fold compared to native PNP and
a kcat reduced by 12-fold and a Km
increased by 3-fold when compared
to Leuko-PNP (Table 1). Similarly, the
H64W-Leuko-PNP has a kcat reduced by
6-fold and a Km increased by 4-fold
when compared to native PNP and akcat reduced by 5-fold and a Km increased by 5-fold when
compared to Leuko-PNP (Table 1). Similar effects on the kinetic
parameters for inosine phosphorolysis were observed for
the fluorinated mutants (H257-6FW-leuko-PNP and H64-6FW-
Leuko-PNP), indicating that the incorporation of 6FW has only
modest effects on the catalytic activity.
DADMeImmG inhibition constants (Ki and Ki*) for the H257W-
Leuko-PNP mutant were increased by 0.6- and 7-fold when
compared to native PNP and reduced by 3-fold and increased
by 12-fold, respectively, when compared to the Leuko-PNP
enzyme (Table 1). In the case of the H64W-Leuko-PNP mutant,
the Ki for DADMeImmG was unaltered when compared to native
PNP and reduced by 3-fold when compared to Leuko-PNP,
whereas the Ki for DADMeImmG was increased by 2-fold
when compared to native PNP and increased by 3-fold when
compared to Leuko-PNP (Table 1). Remarkably, slow onset
inhibition (Ki*) was not observed in either of the fluorinated
mutants (H257-6FW-Leuko-PNP and H64-6FW-Leuko-PNP),
whereas the Ki was essentially unaltered in both fluorinated
enzymes (relative to the unfluorinated parent molecules). A
similar loss of slow onset inhibition with Immucillin-H has also
been observed in H257 mutants (Murkin et al., 2007). Despite
the four amino acid substitutions and the incorporation of a fluo-
rinated amino acid (the percentage of 6FW incorporation was
75%, as determined by mass spectrometry) at the active-
site, the H257W-Leuko-PNP and H64W-Leuko-PNP mutants
are active and provide useful active-site probes to study theª2013 Elsevier Ltd All rights reserved 213
Figure 2. Structural Elements of the Human
PNP Homotrimer
(A) The ternary complex with one of the subunits
bound to DADMeImmG and phosphate. The red
rectangle shows the location of the active site near
the subunit interface.
(B) Catalytic site residues of human PNP. The
positions of active-site residues of human PNP
in the sulfate bound form (yellow) are over-
lapped with the ternary complex with bound
DADMeImmG and phosphate (green).
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regions.
19F-NMR of H257-6FW-Leuko-PNP
The 19F-NMR spectrum of phosphate-bound H257-6FW-Leuko-
PNP in 50 mM potassium phosphate buffer at pH 7.4 shows the
presence of two distinct and clearly resolved signals at 122.7
and 126.4 ppm (Figure 3A, black line). As there is a single fluo-
rine label in this mutant, the 6FW in the 257-helix region adopts
two conformations with distinct environments. Preliminary para-
magnetic relaxation effect (PRE) experiments using Omniscan
showed a larger effect on intensity on the signal at 122.7, sug-
gesting that this conformation is more solvent exposed (data not
shown). The integrated area of these two distinct NMR signals is
3:1, indicating that the 122.7 ppm conformation is favored
over the 126.4 ppm conformation.
When a nuclei experiences different chemical environments
on the NMR timescale, it is in chemical exchange. The rate of
chemical exchange is affected by temperature. At low tempera-
ture, interconversion slows beyond the NMR range and the 19F
spectrum consists of distinct peaks. Increased temperature
broadens and then merges the peaks into an average position.
No evidence of chemical exchange between these conforma-
tions was observed after collecting 19F-NMR spectra of H257-
6FW-Leuko-PNP at 288 K, 298 K, and 310 K. This supports
slow conformational exchange, conformers that are not in
exchange, or different conformations in each monomer of the
PNP trimer. Negative cooperativity between PNP subunits is
known to occur upon binding of inhibitors (Ghanem et al.,
2009b; Miles et al., 1998), showing that conformational alter-
ations in one subunit can be transmitted to neighboring subunits.
Thus, the two signals observed in 50 mM phosphate (pH 7.4)
could arise from equilibrium between two major conformations
located in separate subunits.
Enzymes achieve their reaction rate enhancement by lowering
the energetic barrier to the transition state through dynamic
interactions (Schramm, 2005). Transition-state analog inhibitors
are designed to mimic the geometry and electrostatics of the
transition state and convert the dynamic interactions into ther-
modynamic stable states. Structural rearrangements associated
with transition-state analog inhibitor binding are expected to
mimic the geometry of the enzyme during catalysis. The effect
of ligand binding on the conformation of the His257-region was
examined in an equimolar complex of the transition-state analog214 Chemistry & Biology 20, 212–222, February 21, 2013 ª2013 Elseinhibitor DADMeImmG with the H257-6FW-Leuko-PNP mutant
in phosphate buffer. In this complex, the two signals observed
in the PNP-phosphate complex disappear, and a single signal
at 123.3 ppm appears (Figure 3A, red line). A similar behavior
is observed in a complex of PNP-DATMeImmH-phosphate, but
here the single signal observed upon inhibitor binding is at
122.5 ppm (Figure 3A, blue line). These small differences in
chemical shift between the DADMeImmG and DATMeImmH
complexes represent small differences in the chemical environ-
ments of the fluorine probe in each complex. Upon binding of
the transition-state analog, the fluorine probes located in the
three monomers experience identical environments in the reor-
ganized catalytic sites.
In PNP-phosphate, the H257-6FW-region is flexible and able
to exchange between two conformations or exist in different
stable conformations to produce two distinct signals in the
19F-NMR spectrum (Figure 3A, black line). In PNP-inhibitor-
phosphate complexes, the H257-6FW-region is locked into a
single conformation by interactions with the tightly bound tran-
sition-state analog inhibitor and phosphate. Similar 19F-NMR
effects occur upon binding of substrates and inhibitors in other
systems (Hoeltzli and Frieden, 1994; Liu et al., 2012; Salopek-
Sondi and Luck, 2002).
Phosphate binding is known to induce structural changes in
PNP (Ghanem et al., 2008, 2009b), and we tested the behavior
of the fluorine NMR spectrum of the H257-6FW-Leuko-PNP
mutant in the absence of phosphate (50 mM Tris-HCl buffer
[pH = 7.4]) to compare it with PNP-phosphate. The spectrum
of H257-6FW-Leuko-PNP without phosphate or inhibitor shows
a major sharp signal at 124.6 ppm and a minor broad signal
at 123.6 ppm (Figure 3B). These nearly overlapping signals
suggest two conformational states with relatively similar environ-
ments. Upon addition of an equimolar amount of DADMeImmG,
the minor, broad signal at 123.6 ppm disappears and is re-
placed by a sharper signal that appears at122.4 ppm, whereas
the 124.6 ppm signal remains unaffected (Figure 3B, red line).
The lack of a full conversion to a single signal upon binding of
inhibitor is consistent with a reduced affinity for DADMeImmG
in the absence of phosphate.
Native and Leuko-PNPs copurify with tightly bound hypo-
xanthine to give a stoichiometry of 0.7 to 1.0 per enzyme
monomer. Phosphate binding facilitates the release of hypoxan-
thine (Edwards et al., 2009; Ghanem et al., 2008, 2009b). Like-
wise, H257-6FW-Leuko-PNP copurifies with bound guaninevier Ltd All rights reserved
Figure 3. 19F-NMR Spectra of H257-6FW-Leuko PNP
(A) 19F-NMR spectrum of H257-6FW-leuko PNP bound to phosphate (black
line), 19F-NMR spectrum of H257-6FW-leuko PNP bound to DADMeImmG and
phosphate (red line), and 19F-NMR spectrum of H257-6FW-leuko PNP bound
to DATMeImmH and phosphate (blue line).
(B) 19F-NMR spectrum of H257-6FW-leuko PNP bound to guanine/hypoxan-
thine in Tris-HCl buffer (pH 7.4) (black line) and 19F-NMR spectrum of
H257-6FW-leuko PNP bound to guanine/hypoxanthine and DADMeImmG in
Tris-HCl buffer (pH 7.4) (red line).
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enzyme monomer (data not shown). The guanine content
suggests a greater affinity for this base relative to hypoxanthine
for this mutant. Crystal structures of H257W-Leuko-PNP without
phosphate (see below) also show guanine or hypoxanthine
bound to the phosphate-free protein but not to the phos-
phate-bound protein. Altogether, these observations suggest
that the sharper signal at 124.6 ppm arises from a 257-region
with a restricted movement because of a tightly bound guanine,
and the broad signal at 123.6 ppm arises from a flexible
257-region in the apo protein (or subunits). This idea is sup-
ported by the 123.6 ppm peak being readily affected by the
binding of inhibitor (Figure 3B) and that phosphate and charcoal
treatment (known to partially remove PNP from hypoxantine or
guanine) of H257-6FW-Leuko-PNP followed by dialysis against
50 mM Tris-HCl buffer (pH = 7.4), reduced the intensity of the
124.6 ppm signal and the guanine content of this protein
(data not shown).Chemistry & Biology 20, 212X-Ray Crystallography of [6-F-Trp]-H257W-Leuko PNP
Crystal structures were determined for H257W-Leuko-PNP in
Tris-HCl buffer (pH = 7.4) (PDB code 4ECE), H257W-Leuko-
PNP bound to phosphate and DADMeImmG (PDB code 4EB8),
H257-6FW-Leuko-PNP bound to phosphate and DADMeImmG
(PDB code 4EAR), and H257W-Leuko-PNP bound to phosphate
(PDB code 4GKA) to aid in the interpretation of the NMR spectra
(Table 2) (Figures 4A and 4B; Figure S1 available online). An over-
lap of the crystal structures of the H257W-Leuko-PNP bound to
DADMeImmG and phosphate, H257W-Leuko-PNP in Tris-HCl
buffer (pH = 7.4) (guanine bound), and the H257W-Leuko-PNP
in phosphate buffer (pH = 7.4) (phosphate bound) is shown in
Figure 4A (green, yellow, and blue, respectively). Also, an overlap
of the WT PNP and H257W-Leuko-PNP both bound to
DADMeImmG and phosphate is shown in Figure S1. The overall
structures of these proteins overlap well, except for the active-
site residues Ser33, His64, and Trp257, which show significant
conformational rearrangements between the different ligand-
bound forms. These changes are essentially the same as the
ones observed in native PNPs (Figure 2B). Ser33 is located
at the edge of a b sheet region that ‘‘slides’’ 4 A˚ toward the
active site upon binding of phosphate and inhibitor to form
a catalytic triad with phosphate, His86 and His64 (Figures 4A
and 4B). His64 is located in an unstructured and flexible loop
region that is positioned 17 A˚ away from the active site in
the guanine-bound PNP. This residue moves 5 A˚ toward
the active site upon binding of phosphate and becomes orga-
nized at the active site in the PNP-inhibitor-phosphate tertiary
complex, where it interacts with Ser33 and His86 (Figures 4A
and 4B).
Similarly, Trp257 adopts different conformations depending
on which ligand is bound to the active site. Interestingly, no elec-
tron density is observed for the 257-region in the crystal structure
of H257W-Leuko-PNP bound to phosphate, indicating a highly
mobile or disordered region (Figure 4A, dashed blue line). The
structures agree with the 19F-NMR data showing two signals in
the phosphate-bound sample. In Tris-HCl buffer (no phosphate)
the PNP active sites are partially occupied (0.8/monomer) with
guanine and hypoxanthine and in this case the Trp257 side chain
faces the active site (Figures 4A and 4B). In the absence of
a ribose moiety and phosphate, the bulky Trp side chain fits
nicely into the active-site cavity. Shielding the hydrophobic Trp
side chain from the polar solvent environment should stabilize
this conformation. In the tertiary complex with phosphate and
inhibitor, the fully occupied active site excludes the tryptophan
side chain from the active site toward the polar solvent (Figures
4A and 4B). This solvent-exposed conformation is stabilized
by hydrogen bond interactions with Glu258 and Asp157 from
the neighboring subunit. These residues face away from the
Trp side chain in the guanine-bound form of PNP but flip to-
ward the Trp side chain upon inhibitor and phosphate binding
(Figure 4B).
The crystal structure of H257-6FW-Leuko-PNP bound to
phosphate and inhibitor almost perfectly overlaps with its
unfluorinated homolog, except for the Glu258 residue. The elec-
tronegative fluorine atom apparently decreases the hydrogen
bonding character of the indole nitrogen in the fluorinated
tryptophan, thus reducing the strength of its interaction with
Glu258. Despite this small difference, the overall similarity of–222, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 215
Table 1. Comparison of the Steady-State Kinetic Constants and Inhibition Constants for Native, Leuko, H257W-Leuko, H64W-Leuko,
H257-6FW-Leuko, and H64-6FW-Leuko PNPs with Inosine as a Substrate and DADMeImmG as an Inhibitor
WT PNP Leuko PNP H257W Leuko H257-6FW Leuko H64W Leuko H64-6FW Leuko
Kcat (s
1) 47 ± 0.12 36 ± 1 3 ± 0.1 3 ± 0.1 8 ± 0.16 7.9 ± 0.22
Km (uM) 68 ± 8 50 ± 3 136 ± 12 121 ± 14 259 ± 39 240 ± 19
Kcat/Km 6.9 3 10
5 7.2 3 105 2.2 3 104 2.5 3 104 3.1 3 104 3.3 3 104
DADMeImmG Inhibition
Ki (pM) 100 ± 10 376 ± 63 151 ± 16 119 ± 6 109 ± 17 80 ± 4
Ki*(pM) 14 ± 2 9 ± 1 110 ± 10 NA 27 ± 6 NA
NA, not applicable.
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does not significantly perturb the structure of H257W-Leuko-
PNP.
In summary, PNP crystal structures with phosphate and
DADMe-ImmG (4EB8 and 4EAR; Table 2) show the His64-loop
in the closed conformation with W257 pointing away from the
active site. Without phosphate and DADMe-ImmG but with
guanine (4ECE; Table 2), the His64-loop has an open conforma-
tion and W257 is pointing toward the active site. With the PNP-
phosphate structure (4GKA; Table 2), the W257-region was not
resolved in the electron-density map.
DADMeImmG Titration of H257-6FW-Leuko-PNP
The 19F-NMR spectrum of H257-6FW-Leuko-PNP in 50 mM
phosphate buffer (pH 7.4) shows two distinct signals at 122.7
and126.4 ppm (Figure 3A, black line). These two signals disap-
pear, and a distinct signal at 123.3 ppm appears upon binding
of the transition-state inhibitor DADMeImmG (Figure 3A, red
line). A substoichiometric titration of the transition-state analog
inhibitor DADMeImmG into H257-6FW-Leuko-PNP showed the
intensity of the signal at 122.7 ppm to decrease and the new
signal at 123.3 ppm to appear, while the signal at 126.4
ppm remained unchanged at 1/9 catalytic site stoichiometry of
inhibitor (Figure 5). As more equivalents of inhibitor are added,
this pattern continues until one monomer (1/3 equivalents of
DADMeImmG) of the trimeric enzyme is saturated. With only
one of the three catalytic sites filled, the signal at 122.7 ppm
is reduced to a small shoulder, while the signal at 123.3 ppm
increases in intensity, and the signal at 126.4 ppm is slightly
reduced in intensity. When two of the three sites are filled (2/3
equivalents of DADMeImmG), the initial signals at 122.7 ppm
and 126.4 ppm disappear, leaving behind only the sharp sig-
nal at 123.3 ppm. Thus, the structural change for 6FW is
completed at the third site by cooperative changes induced
from the neighboring subunits. Addition of the third equvalent
of DADMeImmG causes no additional changes in linewidth or
intensity.
The two initial signals at 122.7 and 126.4 ppm are different
conformations of the 257-region or different positions of the
6FW-257 side chain. As the 122.7 ppm signal is the first to
be titrated, the spectra suggest that this conformation more
readily responds to inhibitor saturation, whereas the conforma-
tion represented by the126.4 ppm signal ismore directly linked
to inhibitor binding. (Saturation equals binding to all [three] active
sites. Binding refers to a single binding event to one of the active
sites.) The substoichiometric saturation of the enzyme demon-216 Chemistry & Biology 20, 212–222, February 21, 2013 ª2013 Elsestrates that the conformational status of the flexible 257-region
is transmitted between subunits.
19F-NMR of H64-6FW-Leuko-PNP
His64 is located in an unstructured and flexible random-coil
region that changes its position depending on the ligand bound
at the active site (Figures 4A and 4B). The range of motion of
this loop includes a fully open conformation in the guanine-bound
form to a fully closed loop conformation in the phosphate and
inhibitor-bound complex, where His64 hydrogen bonds with
the active site phosphate. Upon phosphate binding, this loop
adopts an intermediate conformation between the open and
closed forms (Figures 4A and 4B). The dynamic characteristics
of these conformations were examined by 19F-NMR on the
H64-6FW-Leuko-PNP mutant with bound guanine, with phos-
phate, and with phosphate and inhibitor bound (Figure 6). One
signal was observed at 121 ppm for the guanine-bound com-
plex, and a signal at 121.3 ppm with a shoulder at 121 ppm
was observed for the phosphate-bound complex. No evidence
of chemical exchange was observed after collecting 19F-NMR
spectra at 288 K, 298 K, and 310 K. The single signal for both
of these complexes and the lack of a temperature effect suggests
this loop to be in fast chemical exchange. The broad signal
reflects the average conformation adopted by this flexible loop.
Previous molecular dynamic calculations predicted this loop to
be the most mobile region of PNP (Hirschi et al., 2010), and this
is supported by the NMR results. Human PNP structures from
the PDB reveal the His64 loop region to show consistently high
B-factors. The mobility of this region is supported by the 19F-
NMR spectrum of H64-6FW-Leuko-PNP bound to one equiva-
lent of inhibitor and phosphate showing a single sharp signal at
121.5 ppmwith a shoulder at121 ppm reminiscent of the sig-
nal observed in the guanine-PNP. The shoulder suggests that
evenunder saturating inhibitor conditions (Table 1) this loop is still
able to move away from the inhibitor-bound conformation.
In the crystal structure of H257W-Leuko-PNP with phosphate,
two monomers of the trimer have an open conformation for
loop-64, and in the third monomer, the 64-loop has a closed
conformation similar to that seen in the crystal structures with
phosphate and inhibitor (DADMe-ImmG). In the ‘‘closed-confor-
mation monomer’’ there was a symmetry-related monomer
next to the 64-loop, with the other two monomers having an
open-conformation 64-loop. There are no other monomers or
symmetry-related monomers in close proximity. This type of
crystal packing forces the loop-64 to stay closed or the closed
64-loop of one monomer allowed the type of crystal packingvier Ltd All rights reserved
Table 2. Data Collection and Structural Refinement Statistics
H257W-LeukoPNP-DADMe-
ImmG-PO4 (PDB code 4EB8)
H257W(f)-LeukoPNP-
DADMe-ImmG-PO4
(PDB code 4EAR)
H257W-LeukoPNP-
PO4 (PDB code 4GKA)
H257W-LeukoPNP-
Guanine (PDB code 4ECE)
Data Collection Statistics
Space Group P212121 P212121 P21 P21
Unit cell parameters a (A˚) 55.75 55.92 53.88 77.55
b (A˚) 131.04 131.10 233.67 129.68
c (A˚) 137.50 137.68 70.08 104.35
b () – – 97.33 105.29
Temperature (K) 100 100 100 100
Wavelength (A˚) 1.075 1.075 1.075 1.075
Resolution (A˚) 50–2.30 (2.38–2.30) 50–1.70 (1.73–1.70) 50–2.20 (2.28–2.20) 50–2.60 (2.69–2.60)
Rmerge (%) 9.7 (82.8) 5.8 (91.4) 10.3 (87.6) 7.0 (87.2)
Completeness (%) 99.9 (100) 98.3 (97.4) 100 (100) 100 (100)
I/sI 20.8 (2.2) 47.3 (2.6) 19.4 (2.1) 26.2 (2.0)
Unique reflections 45,728 (4,476) 110,270 (5,375) 86,349 (8,627) 61,417 (6,104)
Redundancy 6.0 (5.9) 8.0 (8.0) 4.2 (4.2) 4.2 (4.2)
Mosaicity () 0.9 0.4 0.5 0.3
B-factor from Wilson plot (A˚2) 43 28 33 69
Refinement Statistics
Resolution (A˚) 47.48–2.30 41.24–1.70 45.29–2.20 49.04–2.60
Total number of reflections 45,558 110,107 86,296 61,129
Working set: number of reflections 43,257 104,515 81,976 58,023
Rfactor (%) 18.11 17.47 18.80 22.15
Test set: number of reflections 2,301 5,592 4,320 3,106
Rfree (%) 22.76 20.29 23.20 26.10
Protein atoms 6,722 (A,B,C)a 6,753 (A,B,C)a 12,645 (A,B,C,D,E,F)a 13,261 (A,B,C,D,E,F)a
Water atoms 324 579 404 306
DADMe-ImmG atoms 60 60 – –
Phosphate atoms 15 15 30 –
Guanine atoms – – – 66
Ethylene glycol atoms 8 – – –
Glycerol atoms 12
Geometry Statistics
Rmsd (bond distance) (A˚) 0.01 0.01 0.01 0.01
Rmsd (bond angle) () 1.51 1.49 1.40 1.35
Rmsd B
Main chain bonded atoms (A˚2) 1.99 1.38 1.90 1.87
Side chain bonded atoms (A˚2) 2.74 2.25 2.48 2.26
Average B
Main-chain atoms (A˚2) 45.70 36.18 45.82 59.27(A,B,C)/85.49(D,E,F)
Side-chain atoms (A˚2) 49.76 41.36 50.38 62.45(A,B,C)/88.54(D,E,F)
Water atoms (A˚2) 45.51 45.63 42.48 55.14
DAD-Me-ImmG atoms (A˚2) 32.68 26.06 – –
Phosphate atoms (A˚2) 32.05 26.29 40.34 –
Guanine atoms (A˚2) – – – 48.63
Ethylene glycol atoms (A˚2) 47.98 – – –
Glycerol atoms (A˚2) – – 47.83 –
Ramachandran plot
Most favored region (%) 93.1 93.5 93.5 93.3
(Continued on next page)
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Table 2. Continued
H257W-LeukoPNP-DADMe-
ImmG-PO4 (PDB code 4EB8)
H257W(f)-LeukoPNP-
DADMe-ImmG-PO4
(PDB code 4EAR)
H257W-LeukoPNP-
PO4 (PDB code 4GKA)
H257W-LeukoPNP-
Guanine (PDB code 4ECE)
Additionally allowed regions (%) 6.3 5.9 6.1 5.9
Generously allowed regions (%) 0.1 0.1 0 0.3
Disallowed regions (%)b 0.4 0.4 0.4 0.4
Rsmd, root-mean-square deviation.
aABC chains form one trimer and DEF belong to another trimer.
bThr221 of eachmonomer is close to allowed regions in the Ramachandran plot. In the crystal structures, Thr221 locates in one of the active-site loops.
Chemistry & Biology
19F-NMR of Human Purine Nucleoside Phosphorylaseseen with this crystal structure. Therefore, there is crystallo-
graphic ambiguity for the position of the 64-loop in the phos-
phate bound structure.
DISCUSSION
19F-NMR as a Structural Probe
Structural changes upon ligand binding by 19F-NMR comple-
mented with X-ray crystallography have been used in several
protein systems, including D-galactose chemosensory receptor
(Luck and Falke, 1991), dihydrofolate reductase (Hoeltzli and
Frieden, 1994), leucine-specific binding protein (Salopek-Sondi
and Luck, 2002), calmodulin (Kitevski-LeBlanc et al., 2009),
and G protein-coupled receptors (Liu et al., 2012). These exam-
ples demonstrated the utility of 19F-NMR as a tool for defining
structure-activity relationships. Insertion of specific 6FWs as
catalytic site probes to understand transition-state analog
effects on catalytic site functional loops and dynamics, coupled
with kinetic and crystallographic analyses, represents a depar-
ture from previous uses of protein 19F-NMR.
The 19F-NMR and crystallographic data establish the ligand-
dependent structural changes and implicate these conforma-
tional movements in the catalytic cycle. The His257 and
His64 regions of the catalytic sites adopt ‘‘open’’ or ‘‘closed’’
conformations, depending on the ligands bound to the active
site. The His64-loop undergoes the more dramatic conforma-
tional alteration (Figures 4A and 4B). These observations
support the molecular dynamic simulation predictions that the
His64-loop is the most mobile part of hPNP followed by the
His257-region (Hirschi et al., 2010). The calculations also pre-218 Chemistry & Biology 20, 212–222, February 21, 2013 ª2013 Elsedicted different degrees of mobility for the His257-region and
His64-loop, depending on the bound ligand. High mobility
was predicted for the substrates inosine and phosphate and
for the first-generation transition-state analog immucilin-H.
Second- and third-generation transition-state analogs, like
DADMeImmH and DATMeImmH, appear to cause more
restricted conformations (Hirschi et al., 2010). Examination of
the His257-region and His64-loop in human PNP structures in
the PDB shows that the His257-region faces away from the
active site in the sulfate-bound complex but orients toward
the active site when substrate or transition-state analogs are
bound. The His64-loop is positioned distal to the active site
with substrates or immucillin-H bound but adopts a closed
conformation with the transition-state analogs DADMeImmG
and DATMeImmH that more closely resemble the transition
state of human PNP.
Relevant Catalytic Site Motions
Our F-tryptophan structural data for human PNP suggest
a sequential order for the dynamic motions of the His257-region
and His64-loop during catalysis. Previous fluorometric titrations,
pre-steady-state-kinetics, equilibrium ultrafiltration binding and
laser T-jump fluorimetry support a random path for formation
of the catalytically relevant tertiary complex; PNP-nucleoside-
phosphate (Ghanem et al., 2008). Upon binding of phosphate
and nucleoside (inosine or guanosine), the His257-region moves
toward the active-site cavity to facilitate the 50-OH nucleoside
anchoring and formation of the oxygen stack structure;
H257:Nd-O50-O40-Op. These interactions of the His257-region
in turn drive the His64-loop into the closed conformation andFigure 4. Human PNP Complexes: Struc-
tural Overlays of the Catalytic Site
(A) Overlap of the active-site residues of H257W-
Leuko PNP bound to hypoxanthine (yellow),
H257W-Leuko PNP bound to phosphate (light
blue), and H257W-Leuko PNP bound to DAD-
MeImmG and phosphate (green). Double-headed
red arrows denote movements in the His257-
region and His64 loop.
(B) Overlap of the positions of active-site residues
of H257W-Leuko PNP bound to hypoxanthine
(yellow), H257W-Leuko PNP bound to DAD-
MeImmG and phosphate (green), and H257-6FW-
leuko PNP bound to DADMeImmG and phosphate
(purple).
See also Figure S1 and Movie S1.
vier Ltd All rights reserved
Figure 5. DADMeImmG Titration of H257-6FW-Leuko PNP
19F-NMR spectral changes of H257-6FW-leuko PNP upon the addition
of substoichiometric amounts of DADMeImmG in the presence of 50 mM
phosphate (pH 7.4).
Figure 6. 19F-NMR Spectra of H257-6FW-Leuko PNP
19F-NMR spectrum of H257-6FW-leuko PNP bound to guanine/hypoxanthine
(bottom), 19F-NMR spectrum of H257-6FW-leuko PNP bound to phos-
phate (middle), and 19F-NMR spectrum of H257-6FW-leuko PNP bound to
DADMeImmG and phosphate (top).
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(Figures 4A and 4B). Interactions of PNP with phosphate are
known to strongly polarize the phosphate to create amore highly
reactive oxygen nucleophile (Deng et al., 2004). These confor-
mational states provide a favorable arrangement for loss of the
N-ribosidic bond via the His257 interactions and capture of the
ribocation via the His64-loop activation of the phosphate nucle-
ophile. A movie showing the relevant catalytic site motions of
human PNP upon binding of phosphate and transition-state
inhibitor was generated using the morph server (Krebs and Ger-
stein, 2000) to show the active-site conformational rearrange-
ments (Movie S1).
Transition-State Formation
Nucleoside phosphorolysis by human PNP involves the forma-
tion of a fully developed ribocation transition state (Lewandowicz
and Schramm, 2004). Past the transition-state barrier, C1 of the
ribocation migrates to the activated, immobilized phosphate
anion to complete the reaction coordinate in a motion termed
‘‘nucleophilic displacement by electrophile migration’’ (Fedorov
et al., 2001). Proper positioning and organization of the His64
and His257 regions of the catalytic site are required for both
steps. Closure of catalytic site loops and flaps are often thought
to protect reactive intermediates from solvent participation.
Ribocations are sensitive to water attack, which would cause
D-ribose formation instead of the desired ribose 1-phosphate
product in PNP. Although PNP can form ribose from nucleosides
when phosphate is not present, the transition state lifetime of
PNP when phosphate is present is around 10 fs (Saen-Oon
et al., 2008b), too short to permit water diffusion and requiring
the exquisitely accurate placement of phosphate, ribocation,
and purine base in the catalytic site. Disruption of the His257
loop by His257Gly does not lead to ribose formation but causes
N3-isoinosine formation, a chemical consequence of catalytic
site misalignment (Ghanem et al., 2009a). Open and closed
representations of the active site of human PNP with docked
DADMeImmG and phosphate show the closed conformation of
the active-site region of human PNP to effectively enclose theChemistry & Biology 20, 212substrates during catalysis, with a small opening near the ribose
moiety that is capped by Phe200 contributed from the neigh-
boring subunit (Figure 7). These structural changes generate
the appropriate geometry for catalysis.
Product Release
Following catalysis, product release requires both the His257-
region and the His64-loop to open for the release of a-D-ribose
1-phosphate. This step is efficient and fast relative to purine
base release, the rate-limiting step in human PNP (Ghanem
et al., 2009b). The motions defined here are therefore linked to
the overall rate of catalysis by human PNP. There are no equiv-
alent dynamic motions related to release of the purine ring,
making its release the slowest step in the overall catalytic cycle.
The relatively tight binding of purine bases is also evident in the
tightly bound purine bases found in purified PNP protein. The
catalytic site titration experiments monitored here by 19F-NMR
also give insights into the negative cooperativity known for
binding of transition-state analogs to PNPs (Miles et al., 1998).
Structural changes at adjacent sites result in conformational
changes that occur in a negative cooperative manner to partially
occlude access of next-ligand binding and give rise to the
observed binding profile.
SIGNIFICANCE
Dynamic motions in enzyme catalysis occur on timescales
ranging from milliseconds for protein conformational rear-
rangements to femtoseconds for single bond vibrations.
How each time domain is linked to enzyme function is in
debate (Hammes-Schiffer and Benkovic, 2006). The catalytic
turnover rate of human PNP is on the millisecond timescale,
but the transition-state lifetime is only 10 fs; thus, slower
conformational changes limit the catalytic cycle (Saen-
Oon et al., 2008b). Crystal structures and computational
dynamics suggested that two regions of the protein, near
His257 and His64, are the most flexible (Hirschi et al.,–222, February 21, 2013 ª2013 Elsevier Ltd All rights reserved 219
Figure 7. Surface Representation of the
Active-Site Region of Human PNP
(A) Surface representation of the open con-
formation of the active site of human PNP with
DADMeImmG and phosphate.
(B) Surface representation of the closed confor-
mation of the active site of human PNP with
DADMeImmG and phosphate showing Phe159
from the neighboring subunit (green stick model).
See also Movie S1.
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crystal structures show at least two distinct conformations
for these parts of the PNP protein. One is open to allow the
substrate to bind, and the other is closed to permit interac-
tions with the reactants bound in the catalytic site and
formation of the transition state. The 19F-NMR experiments
presented here provide direct evidence for the presence of
multiple active-site conformations of F-Trp in the solution
structure of human PNP. These flexible portions of the
protein open and close fast relative to the overallmillisecond
catalytic turnover rate. The rate-limiting step in the human
PNP catalysis is release of the purine ring. There is no highly
flexible protein element to help clear the catalytic site of
the purine ring. This slow purine release is a design charac-
teristic of human PNP, readily evident in the copurification of
PNP and tightly bound guanine or hypoxanthine at the
catalytic sites.
EXPERIMENTAL PROCEDURES
Site-Directed Mutagenesis
Mutagenesis was performed using the QuickChange Lightning site-directed
mutagenesis kit from Stratagene (La Jolla, CA, USA). Pairs of complementary
primers (synthesized and purified by Invitrogen [Carlsbad, CA, USA]) were de-
signed to introduce the required mutations in the Leuko-PNP gene cloned into
the pCRT7/NT-TOPO (Invitrogen) plasmid (Ghanem et al., 2008). The oligonu-
cleotide pairs (mutated codons are in boldface) were as follows: H257W-fw
50 GAAAGCCTGGAGAAGGCCAACTGGGAAGAAGTCTTAGCAGCTGGC 30,
H257W-rv 50 GCCAGCTGCTAAGACTTCTTCCCAGTTGGCCTTCTCCAGGCT
TTC 30 and H64W-fw 50 GAAGTACAGTGCCAGGTTGGGCTGGCCGAC
TGGTG 30, H64W-rv 50 CACCAGTCGGCCAGCCCAACCTGGCACTGTACTTC
30. Mutagenesis was performed in accordance with the manufacturer’s
protocol, and the reaction products were transformed into the Escherichia
coliBL21(DE3)pLysS (Invitrogen) strain for selection and expression purposes.
The presence of the mutated codons in the hPNP gene was confirmed by DNA
sequencing.
Expression Purification of Unlabeled Enzymes
Native, H257W-leuko, and H64W-Leuko enzymes were expressed and
purified to homogeneity as judged by SDS-PAGE by following the same
procedure previously described for native PNP (Lewandowicz and Schramm,
2004).
Expression and Purification of 19F-Labeled Enzymes
19F-labeled enzymes (H257W-leuko and H64W-Leuko) were expressed in
E. coli BL21(DE3)pLys (Invitrogen) cells containing the hPNP mutant
constructs cloned into the pCRT7/NT-TOPO (Invitrogen) plasmid. Cells
were grown in M63 minimum medium supplemented with glucose and
100 mg ml1 ampicillin, at 37C. 6-Fluoro-DL-tryptophan (Sigma-Aldrich,220 Chemistry & Biology 20, 212–222, February 21, 2013 ª2013 ElseSt. Louis, MO, USA) was added 30 min before IPTG induction (optical
density: 0.8–1) to a final concentration of 0.2 mg ml1. Cells were
allowed to grow for an additional 8 hr and harvested by centrifugation. All
19F-labeled proteins were purified to homogeneity following the same
procedure previously described for native PNP (Lewandowicz and Schramm,
2004).
Activity and Inhibition Assays
Activity assays for native and mutant PNP enzymes with inosine as
a substrate were performed as previously described by monitoring the
conversion of hypoxanthine to uric acid (ε293 = 12.9 mM
1 cm1) (Kim
et al., 1968) in a coupled assay containing 60 munit of xanthine oxidase
and variable concentrations of inosine, in 50 mM phosphate buffer (pH 7.4)
at 25C (Lewandowicz et al., 2003). The slow onset inhibition was mea-
sured following the addition of enzyme to complete assay mixtures con-
taining 1 mM inosine and various inhibitor concentrations (Kicska et al.,
2002; Rinaldo-Matthis et al., 2007). Enzyme was added to assay mixtures
followed by monitoring rates of product formation for 1–2 hr to determine
both the initial reaction rates and to determine if slow onset inhibition
occurred. Protein and inhibitor concentrations were determined by their
corresponding extinction coefficients, 23,380 M1 cm1 for the single trypto-
phan mutants, 8.92 M1 cm1 for DADMeImmG and 9.54 M1 cm1 for
DATMeImmH.
Enzymatic Digestion of Proteins and MALDI-TOF Mass
Spectrometry Analysis
In order to determine the extent of 6-fluoro tryptophan incorporation into the
modified enzymes, wild-type PNP and 6-F-Trp PNP were digested by trypsin
following the standard digestion protocol. The digested peptides were then
purified by C18 ZipTip (Millipore, Billerica, MA, USA) for mass spectrometry
analysis. MALDI-TOF mass spectrometry analysis of the digested peptides
was performed on a Voyager Biospectrometry DE-STR Workstation (Applied
Biosystems, Foster City, CA, USA) equipped with a nitrogen laser (330 nm).
The instrument was operated in positive ionization mode, and measurements
were performed in linear mode (mass rangem/z 800 to 6000) using a-cyano-4-
hydroxycinnamic acid as a matrix. A saturated matrix solution was prepared in
80% acetonitrile, 19.9% water, and 0.1% TFA (v/v/v). Samples were prepared
using the dried droplet method by spotting 1 ml of matrix solution and 1 ml of
sample solution onto the target. Spectra from 100 to 300 laser shots were
accumulated to produce one spectrum. The instrument was calibrated using
the monoisotopic masses of standard peptides: KPQQFFDLM (MH+1(mi)
1095.56), CQDSETRTFY (MH+1(mi) 1249.52), and YGGFMTSEKSQTPLVT
(MH+1(mi) 1745.84).
19F-NMR Spectroscopy
19F-NMR spectra were acquired on a Bruker DRX 600 MHz (Bruker Biospin,
Billerica, MA, USA) spectrometer equipped with a 5 mm BBFO probe. Unless
otherwise indicated, all one-dimensional spectra were recorded at 25C with
23,542 scans (9 hr acquisition). The time-domain NMR data were multiplied
with an exponential function with a line-broadening factor of 25 Hz prior to
Fourier transformation. The protein concentration for the NMR measurements
was in the range of 0.4–0.8 mM.vier Ltd All rights reserved
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The H257W-leukoPNP was dialyzed against 50 mM Tris buffer at pH 8.5 and
1 mM DTT. The concentration of H257W-hPNP for crystallization was
14 mg/ml in the presence of 1 mMDADMe-ImmG and 5mM phosphate. Crys-
tals were obtained by sitting-drop vapor diffusion with 20% PEG 5000
monomethyl ether, 100 mM Bis-Tris (pH 6.5). Crystals of H257W-leukoPNP-
DADMeImmG were transferred to a fresh drop of the crystallization solution
containing 20% ethylene glycol and flash-cooled. In the case of H257-6FW-
leuko PNP, the protein was dialyzed in 50 mM Tris (pH 7.5), concentrated to
8.0 mg/ml, and DADMe-ImmG and phosphate added to final concentrations
of 0.5 mM and 5 mM, respectively. The H257-6FW-leuko PNP crystals grew
from 20% PEG 1000 in 100 mM Tris (pH 7.0). Prior to flash-cooling at 100 K,
the H257-6FW-leuko PNP-DADMe-ImmG crystal was transferred into the cor-
responding crystallization solution with 26% (w/v). When setting up the apo
H257W-leukoPNPandH257W-leuko PNPwith phosphate crystallization trials,
H257W-leukoPNP was treated the same as the H257-6FW-leuko PNP variant.
The phosphate bound H257W-leukoPNP crystals grew from 16% (w/v) PEG
8000, 20% (v/v) glycerol, 160 mM magnesium acetate, 80 mM sodium caco-
dylate, pH 6.5 solution. These crystals were directly flash-cooled from the
crystallization drop. The crystals of H257W-leuko PNP with 5 mM phosphate
grew from 10% (v/v) 2-propanol, 0.2 M zinc acetate, 0.1M sodium cacodylate,
pH 6.5 solution, and were flash cooled in the crystallization solution containing
27% (v/v) glycerol. All X-ray diffraction data were collected at Beamline X29A
at Brookhaven National Laboratory. All data were processed with HKL3000
(Minor et al., 2006) program suite; data processing statistics are provided in
Table 2.
Structure Determination and Refinement
The crystal structures of H257W-leukoPNP-DADMe-ImmG, H257-6FW-leuko
PNP-DADMe-ImmG, and H257W-leukoPNP with only phosphate were deter-
mined by molecular replacement in MOLREP (Vagin and Teplyakov, 2010) in
the CCP4 program suite (Collaborative Computational Project, Number 4,
1994; Potterton et al., 2003) using the published structure of hPNP (PDB
code 1RR6) as the search model. The phosphate-bound H257W-leukoPNP
crystal structure was determined by using PHASER (McCoy et al., 2007) and
using the same model. All the models were first rebuilt in COOT (Emsley and
Cowtan, 2004) and refined in REFMAC5 (Murshudov et al., 1997). The
DADMeImmG, phosphate, and/or guanine were added at the last stages of
refinement using Fo - Fc map. In the case of phosphate-bound H257W-leuko
PNP, only guanine (and not hypoxanthine) was added because it was the
most abundant molecule that copurified with this mutant. The quality of
all structures was checked by PROCHECK (Laskowski et al., 1993) and
MolProbity (Chen et al., 2010; Davis et al., 2007). The refinement and geometry
statistics are summarized in Table 2.
In the case of the H257W-leuko-PNP crystal structure without phosphate
and inhibitor (4ECE), there are two trimers in the asymmetric unit. One
trimer, consisting of monomers A, B, and C (Table 2), has lower average
temperature factors (B-factors) for the main-chain atoms than the other trimer
(D,E,F). Because of the high B-factors, the electron-density in some regions
of a D,E,F-trimer are not well defined. Accordingly, the trimer composed of
monomers A, B, and C is used for all structural comparisons in this study. In
all the comparisons, the B-monomers of various crystal structures were
utilized.
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